Update: AstraZeneca Q3 Adjusted Earnings, Revenue Rise; Reaffirms 2026 Outlook

06:05 AM EDT, 10/30/2026 (MT Newswires) -- (Updates with details from cost-savings plan in the seventh and eighth paragraphs and latest stock move in the ninth paragraph.) AstraZeneca (AZN) reported fiscal Q3 core net income Friday of $2.79 per diluted share, up 17% from a year earlier. Analysts polled by FactSet expected $2.60. Revenue for the quarter ended Sept. 30 was $16.21 billion, up from $15.19 billion a year earlier. Analysts expected $16.02 billion. The company reaffirmed its 2026 outlook for core EPS and revenue to grow by low double-digit and mid-to-high single-digit percentages, respectively. Analysts surveyed by FactSet expect EPS of $10.24 on revenue of $62.87 billion. AstraZeneca also initiated its three-year Reshaping for Sustainable Growth program, which is expected to cost up to $2 billion in one-time restructuring costs and deliver $1.5 billion in annualized pre-tax run-rate benefits, the company said. The savings generated will continue to be reinvested mostly back into the company's drug pipeline, it said. Shares of the company were 4.3% higher in premarket activity.